THE ARCHIVE
CAN BE TESTED.

Use machine translation and structured extraction to connect original findings, chemical identities and methodological gaps. Human review and prospective experimental benchmarks determine whether the workflow improves decisions.

The latest MSMR surveillance reports 518 heat-stroke and 2,233 heat-exhaustion cases in active-component service members in 2025. Heat-exhaustion incidence declined 9.1%. The burden remains concrete without claiming every category is worsening.

On July 28, 2026 FDA issued 17 revised draft product-specific guidances for certain generic peptide products. The update concerns generic assessment. It does not approve Dalargin or establish an abbreviated route for an Antaeus candidate.

Pharmacology / PK 35% ($525k), chemistry / authenticated material / formulation 20% ($300k), initial safety 15% ($225k), scientific leadership / personnel 15% ($225k), AI / evidence data 5% ($75k), IP / regulatory 5% ($75k), operations / contingency 5% ($75k). Planning estimates, not vendor quotes.

Months 0–3: scientific leadership, contracted laboratory plan and locked protocol. Months 3–9: controlled replication, exposure and safety. Stop advancement by month nine for failed replication or unacceptable safety. Months 9–18: candidate selection only if the gates pass. Clinical development requires follow-on funding.